Governments should use patents to shape the deployment of CRISPR–Cas9 as they have done for past technologies, argues Shobita Parthasarathy.
Read more
Category: biotech/medical – Page 2308
Biohacking raises a host of ethical issues, particularly about data protection and cybersecurity as virtually every tech gadget risks being hacked or manipulated. And implants can even become cyberweapons, with the potential to send malicious links to others. “You can switch off and put away an infected smartphone, but you can’t do that with an implant,” says Friedemann Ebelt, an activist with Digitalcourage, a German data privacy and internet rights group.
Patrick Kramer sticks a needle into a customer’s hand and injects a microchip the size of a grain of rice under the skin. “You’re now a cyborg,” he says after plastering a Band-Aid on the small wound between Guilherme Geronimo’s thumb and index finger. The 34-year-old Brazilian plans to use the chip, similar to those implanted in millions of cats, dogs, and livestock, to unlock doors and store a digital business card.
Kramer is chief executive officer of Digiwell, a Hamburg startup in what aficionados call body hacking—digital technology inserted into people. Kramer says he’s implanted about 2,000 such chips in the past 18 months, and he has three in his own hands: to open his office door, store medical data, and share his contact information. Digiwell is one of a handful of companies offering similar services, and biohacking advocates estimate there are about 100,000 cyborgs worldwide. “The question isn’t ‘Do you have a microchip?’ ” Kramer says. “It’s more like, ‘How many?’ We’ve entered the mainstream.”
Research house Gartner Inc. identified do-it-yourself biohacking as one of five technology trends—others include artificial intelligence and blockchain—with the potential to disrupt businesses. The human augmentation market, which includes implants as well as bionic limbs and fledgling computer-brain connections, will grow more than tenfold, to $2.3 billion, by 2025, as industries as diverse as health care, defense, sports, and manufacturing adopt such technologies, researcher OG Analysis predicts. “We’re only at the beginning of this trend,” says Oliver Bendel, a professor at the University of Applied Sciences & Arts Northwestern Switzerland who specializes in machine ethics.
A team of researchers led by Principal Investigator Dr. Jan Gruber from Yale-NUS College has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.
The study, published in the peer-reviewed international journal Developmental Cell on 8 October 2018, lays crucial groundwork for further research into designing drug combinations that produce the same effect in mammals.
“Many countries in the world, including Singapore, are facing problems related to ageing populations,” said Dr. Gruber, whose lab and research team made the discovery. “If we can find a way to extend healthy lifespan and delay ageing in people, we can counteract the detrimental effects of an ageing population, providing countries not only medical and economic benefits, but also a better quality of life for their people.”
Read more
Cancer is the poster child of age-related diseases, and a recent study sheds light on why the risk of cancer rises dramatically as we age.
Abstract
For many cancer types, incidence rises rapidly with age as an apparent power law, supporting the idea that cancer is caused by a gradual accumulation of genetic mutations. Similarly, the incidence of many infectious diseases strongly increases with age. Here, combining data from immunology and epidemiology, we show that many of these dramatic age-related increases in incidence can be modeled based on immune system decline, rather than mutation accumulation. In humans, the thymus atrophies from infancy, resulting in an exponential decline in T cell production with a half-life of ∼16 years, which we use as the basis for a minimal mathematical model of disease incidence. Our model outperforms the power law model with the same number of fitting parameters in describing cancer incidence data across a wide spectrum of different cancers, and provides excellent fits to infectious disease data.
Read more
Congratulations to the Forest Organics team and their awesome new site — https://www.myforestorganics.com/
